Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Similar articles for PubMed (Select 18251569)

1.

Molecular testing in solid tumors: an overview.

Hunt JL.

Arch Pathol Lab Med. 2008 Feb;132(2):164-7. doi: 10.1043/1543-2165(2008)132[164:MTISTA]2.0.CO;2. Review.

PMID:
18251569
2.

Molecular genetic analysis of oligodendroglial tumors.

Hartmann C, Mueller W, Lass U, Kamel-Reid S, von Deimling A.

J Neuropathol Exp Neurol. 2005 Jan;64(1):10-4. Review.

PMID:
15715080
3.

Unusual thyroid tumors: a review of pathologic and molecular diagnosis.

Hunt JL.

Expert Rev Mol Diagn. 2005 Sep;5(5):725-34. Review.

PMID:
16149875
4.

Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.

Aldape K, Burger PC, Perry A.

Arch Pathol Lab Med. 2007 Feb;131(2):242-51. Review.

PMID:
17284109
5.

Understanding the genotype of follicular thyroid tumors.

Hunt J.

Endocr Pathol. 2005 Winter;16(4):311-21. Review.

PMID:
16627918
6.

Molecular pathology--translating research into clinical practice: an expanding frontier in surgical oncology.

Nordberg ML.

Surg Oncol Clin N Am. 2008 Apr;17(2):303-21, viii. doi: 10.1016/j.soc.2008.01.003. Review.

PMID:
18375354
7.

Molecular events in follicular thyroid tumors.

Kroll TG.

Cancer Treat Res. 2004;122:85-105. Review.

PMID:
16209039
8.

Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.

Reifenberger G, Louis DN.

J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26. Review.

PMID:
12578221
9.

[The oligodendroglioma: the value of histologic and genetic diagnosis in predicting sensitivity to chemotherapy].

Kros JM.

Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1379-85. Review. Dutch.

PMID:
15997690
10.

The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.

McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, Burger PC, Louis DN, Giannini C, Fuller G, Passe S, Blair H, Jenkins RB, Yang H, Ledoux A, Aaron J, Tipnis U, Zhang W, Hess K, Aldape K.

Cancer. 2005 Oct 1;104(7):1468-77.

11.

Molecular testing in lung carcinoma: Quo vadis?

Dacic S, Yousem SA.

Am J Clin Pathol. 2010 Jul;134(1):7-9. doi: 10.1309/AJCPAY77GIUKFCSB. No abstract available.

12.

Oligodendroglioma: pathology and molecular biology.

Engelhard HH, Stelea A, Cochran EJ.

Surg Neurol. 2002 Aug;58(2):111-7; discussion 117. Review.

PMID:
12453646
13.

Oligodendroglial tumors: diagnostic and molecular pathology.

Rodriguez FJ, Giannini C.

Semin Diagn Pathol. 2010 May;27(2):136-45. Review.

PMID:
20860317
14.

Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions.

Ney DE, Lassman AB.

Curr Oncol Rep. 2009 Jan;11(1):62-7. Review.

PMID:
19080743
15.

Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.

Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK.

Cancer. 2010 Jun 15;116(12):2974-83. doi: 10.1002/cncr.25061.

16.
17.

Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.

Cairncross G, Jenkins R.

Cancer J. 2008 Nov-Dec;14(6):352-7. doi: 10.1097/PPO.0b013e31818d8178. Review.

PMID:
19060598
18.

Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression.

Ferrer-Luna R, Mata M, Núñez L, Calvar J, Dasí F, Arias E, Piquer J, Cerdá-Nicolás M, Taratuto AL, Sevlever G, Celda B, Martinetto H.

J Neurooncol. 2009 Dec;95(3):343-54. doi: 10.1007/s11060-009-9944-y. Epub 2009 Jul 12.

PMID:
19597701
19.

Diagnosis and management of oligodendroglioma.

van den Bent MJ.

Semin Oncol. 2004 Oct;31(5):645-52. Review.

PMID:
15497117
20.

Molecular markers in thyroid cancer diagnostics.

Kato MA, Fahey TJ 3rd.

Surg Clin North Am. 2009 Oct;89(5):1139-55. doi: 10.1016/j.suc.2009.06.012. Review.

PMID:
19836489
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk